Actinium Pharmaceuticals (ATNM) Research & Development (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Research & Development of $4.2 million for Q1 2026, down 45.44% year-over-year from $7.7 million in Q1 2025, and down 2.23% quarter-over-quarter from $4.3 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Research & Development (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Research & Development for 15 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 45.44% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $17.6 million (down 43.35% YoY), while the FY2025 annual figure was $21.1 million, down 29.69% from the prior year.
- Research & Development fell to $4.2 million in Q1 2026 per ATNM's latest filing, from $4.3 million in the prior quarter.
- Across five years, Research & Development topped out at $11.6 million in Q3 2023 and bottomed at $4.2 million in Q1 2026.
- Historically, Research & Development has averaged $6.9 million across 5 years, with a median of $6.8 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development jumped 137.69% — and 2025, when it plunged 56.54%.
- Actinium Pharmaceuticals' Research & Development stood at $7.3 million in 2022, then climbed by 10.71% to $8.1 million in 2023, then plunged by 40.74% to $4.8 million in 2024, then declined by 10.68% to $4.3 million in 2025, then dropped by 2.23% to $4.2 million in 2026.
- Business Quant data shows ATNM's Research & Development at $4.2 million in Q1 2026, $4.3 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 97.90 Mn |
| 10 | Actinium Pharmaceuticals | 35.17 Mn | 35.17 Mn | - | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.38 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 7.70 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 9.77 Mn |
| Jun 30, 2024 | 8.83 Mn |
| Mar 31, 2024 | 6.64 Mn |
| Dec 31, 2023 | 8.12 Mn |
| Sep 30, 2023 | 11.62 Mn |
| Jun 30, 2023 | 11.08 Mn |
| Mar 31, 2023 | 7.85 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 6.77 Mn |
| Jun 30, 2022 | 4.66 Mn |
| Mar 31, 2022 | 4.37 Mn |
| Dec 31, 2021 | 5.42 Mn |
| Sep 30, 2021 | 4.71 Mn |